2026 China FIC Innovation and Collaboration Summit

Over the past decade, China’s innovative drug pipeline has experienced explosive growth, becoming an integral part of the global pharmaceutical landscape. In 2025, the total value of cross-border licensing for Chinese innovative drugs surpassed $100 billion, doubling the scale of the previous year. Despite this progress, only about 10% of China’s new drug pipelines have been involved in transactions, leaving immense untapped potential for collaboration.

To bridge this gap, the Zhongguancun FIC Innovative Drug Strategic Development Alliance(ZFIC Alliance) is proud to host 2026 China FIC Innovation & Collaboration Summit during the 2026 JPM Conference. This summit aims to create an efficient communication platform for international5 pharmaceutical companies, investment institutions, and Chinese biotech enterprises.

This summit will provide a comprehensive data-driven interpretation of driving factors, current status, and future trends of Chinese innovative drugs’ explosive growth, offering participants a comprehensive and authentic view of the Chinese innovative drug landscape. In addition, the summit will organise roadshows for a number of selected Chinese innovative drug pipelines that lead globally in terms of development progress, clinical relevance, and underlying transaction value. The event will be a window to discover strategic cooperation opportunities for China’s most innovative drug assets.